Mexico - Delayed Quote MXN

10x Genomics, Inc. (TXG.MX)

150.00

-5.77

(-3.70%)

As of April 4 at 8:34:22 AM CST. Market Open.

10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 8, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company

PR Newswire 9 days ago

TXG
We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 28 days ago

TXG
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products

10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, 2025, in the United States District Court for the District of Delaware, Parse agreed - a week before trial was to start - to a worldwide permanent injunction that prevents it from making, using, selling or offering for sale its planned ATAC and ATAC-Multiome Single Cell products. As part of this cons

PR Newswire last month

TXG
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new product innovations to solidify its position as the best partner for high-performance single cell research at scale. In addition, the company unveiled a robust new product roadmap for its Visium and Xenium portfolios, extending its performance and technology leadership in the rapidly growing field of spatial biology.

PR Newswire last month

TXG
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, at 11:10 a.m. Eastern Time.

PR Newswire 2 months ago

TXG
10x Genomics Full Year 2024 Earnings: EPS Misses Expectations

10x Genomics ( NASDAQ:TXG ) Full Year 2024 Results Key Financial Results Revenue: US$610.8m (down 1.3% from FY 2023...

Simply Wall St. 2 months ago

TXG
10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025.

PR Newswire 2 months ago

TXG
Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology

Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an unprecedented one billion cell dataset to fuel rapid progress in AI model development in biology. CZI is embarking on this landmark initiative in collaboration with partners 10x Genomics, Ultima Genomics, and a group of leading researchers. Industry partners are enabling data generation at unprecedented scale by increasing access to cutting-edge technologies and lowering costs.

PR Newswire 2 months ago

TXG
10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Wednesday, February 12, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be ac

PR Newswire 2 months ago

TXG
10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 7:30 a.m. Pacific Time.

PR Newswire 3 months ago

TXG
U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx products sold by Bruker Corporation (Nasdaq: BRKR), which acquired the product line from NanoString Technologies. To minimize the risk of disruption to ongoing research, 10x Genomics requested a carve-out for GeoMx users who installed an instrument prior to the trial in November 2023.

PR Newswire 3 months ago

TXG

BRKR
10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Wolfe Research 2024 Healthcare Conference on Tuesday, November 19, at 1:00 p.m. Eastern Time.

PR Newswire 5 months ago

TXG
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

Investors in 10x Genomics, Inc. ( NASDAQ:TXG ) had a good week, as its shares rose 3.5% to close at US$16.03 following...

Simply Wall St. 5 months ago

TXG
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative

French TechBio startup Cure51 and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that Cure51 will deploy 10x Genomics' Visium HD as part of its pioneering work to understand the unique biology of exceptional cancer survivors, whose survival mechanisms could hold the key to new therapeutic approaches. Working alongside more than 50 medical institutions, Cure51 intends to collect and analyze tumor tissues from over 1,000 exceptional cancer survivors

PR Newswire 5 months ago

TXG
10x Genomics Reports Third Quarter 2024 Financial Results

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024.

PR Newswire 5 months ago

TXG
10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to democratize access to single cell analysis. The new offerings – GEM-X Flex and GEM-X Universal Multiplex – introduce significant improvements in performance, workflow and cost effectiveness, enabling more researchers to pursue single cell analysis for more applications.

PR Newswire 6 months ago

TXG
10x Genomics Inc (TXG) Q2 2024 Earnings Call Highlights: Navigating Growth Amidst Macroeconomic ...

Despite revenue growth and cash flow positivity, 10x Genomics Inc (TXG) faces headwinds from budget pressures and elongated purchase cycles.

GuruFocus.com 6 months ago

TXG
10x Genomics Announces Preliminary Select Third Quarter 2024 Results

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, 2024.

PR Newswire 6 months ago

TXG
Vanguard Group's Strategic Acquisition in 10x Genomics Inc

On September 30, 2024, Vanguard Group Inc, a prominent investment firm, expanded its portfolio by acquiring an additional 783,673 shares of 10x Genomics Inc (NASDAQ:TXG), a leader in the life science technology sector. This transaction, executed at a price of $22.58 per share, increased Vanguard's total holdings in the company to 10,972,930 shares, marking a significant endorsement of TXG's potential in the healthcare technology market. Founded in 1975 by John C. Bogle, Vanguard Group Inc has revolutionized the investment world with its low-cost, client-focused fund offerings.

GuruFocus.com 6 months ago

TXG
10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting

At the Human Cell Atlas General Meeting held September 29-30 in Milan, Italy, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, shared new details about its upcoming product roadmap and its ongoing strategy to democratize access to single cell analysis.

PR Newswire 6 months ago

TXG

Performance Overview

Return	TXG.MX	S&P 500 (^GSPC)
YTD	-65.91%	-6.70%
1-Year	-81.77%	+8.20%
3-Year	-88.42%	+28.45%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

10x Genomics, Inc. (TXG.MX)

10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025

We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth

10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

10x Genomics Full Year 2024 Earnings: EPS Misses Expectations

10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology

10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products

10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference

Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative

10x Genomics Reports Third Quarter 2024 Financial Results

10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches

10x Genomics Inc (TXG) Q2 2024 Earnings Call Highlights: Navigating Growth Amidst Macroeconomic ...

10x Genomics Announces Preliminary Select Third Quarter 2024 Results

Vanguard Group's Strategic Acquisition in 10x Genomics Inc

10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting

Performance Overview